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Abstract
Background: It is estimated that 9.3% of the population in the United States have diabetes mellitus (DM), 28%
of which are undiagnosed. The high prevalence of DM makes it a common comorbid condition in hospitalized
patients. In recent years, government agencies and healthcare systems have increasingly focused on 30-day
readmission rates to determine the complexity of their patient populations and to improve quality. Thirty-day
readmission rates for hospitalized patients with DM are reported to be between 14.4 and 22.7%, much higher
than the rate for all hospitalized patients (8.5–13.5%). The objectives of this study were to (1) determine the
incidence and causes of 30-day readmission rates for patients with diabetes listed as either the primary reason for
the index admission or with diabetes listed as a secondary diagnosis compared to those without DM and (2)
evaluate the impact on readmission of two specialized inpatient DM services: the Hyperglycemic Intensive Insulin
Program (HIIP) and Endocrine Consults (ENDO).
Methods: For this study, DM was defined as any ICD-9 discharge diagnosis (principal or secondary) of 250.xx.
Readmissions were defined as any unscheduled inpatient admission, emergency department (ED) visit, or
observation unit stay. We analyzed two separate sets of patient data. The first pilot study was a retrospective chart
review of all patients with a principle or secondary admission diagnosis of diabetes admitted to any adult service
within the University of Michigan Health System (UMHS) between October 1, 2013 and December 31, 2013. We
then did further uncontrolled analysis of the patients with a principal admitting diagnosis of diabetes. The second
larger retrospective study included all adults discharged from UMHS between October 1, 2013 and September 30,
2014 with principal or secondary discharge diagnosis of DM (ICD-9-CM: 250.xx).
Results: In the pilot study of 7763 admissions, the readmission rate was 26% for patients with DM and 22% for
patients without DM. In patients with a primary diagnosis of DM on index admission, the most common cause
for readmission was DM-related. In the larger study were 37,702 adult inpatient discharges between October 1,
2013 and September 30, 2014. Of these, 20.9% had DM listed as an encounter diagnosis. Rates for all encounters
(inpatient, ED and Observation care) were 24.3% in patients with DM compared to 17.7% in those without DM
(p < 0.001). The most common cause for readmission in patients with DM as a secondary diagnosis to the index
admission was infection-related.
During the index hospital stay, only a small proportion of patients with DM (approximately 12%) received any DM
service consult. Those who received a DM consult had a higher case mix index compared to those who did not.
Despite the higher acuity, there was a lower rate of ED /observation readmission in patients followed by the DM
services (6.6% HIIP or ENDO vs. 9.6% no HIIP or ENDO, p = 0.0012), though no difference in the inpatient
readmission rates (17.6% HIIP or ENDO vs. 17.4% no HIIP or ENDO, p = 0.89) was noted.
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Conclusions: Patients with both a primary or secondary diagnosis of DM have higher readmission rates. The
reasons for readmission vary; patients with a principal diagnosis of DM have more DM related readmissions and
those with secondary diagnosis having more infection-related readmissions. DM services were used in a small
proportion of patients and may have contributed to lower DM related ED revisits. Further prospective studies
evaluating the role of these services in terms of glucose management, patient education and outpatient follow
up on readmission are needed to identify interventions important to reducing readmission rates.
Background
DM mellitus (DM) is a growing burden in the United
States. It is estimated that 9.3% of the population (29.1
million people) in the United States has DM, and 28% are
undiagnosed [1]. Chronic complications of DM include
retinopathy, neuropathy, nephropathy, an increased risk of
cardiovascular disease and major cardiac events including
myocardial infarction and stroke [2]. The high prevalence
of DM and its complications makes it a common comor-
bid condition in hospitalized patients. This leads to fre-
quent admissions for procedures and interventions during
which patients with DM are reported to have longer
lengths of stay (LOS), increased hospital complications,
and mortality [3–6].
In recent years, government agencies and healthcare
systems are increasingly focused on 30-day readmission
rates as a way to improve quality and also determine
the complexity of patient populations. The Centers for
Medicare and Medicaid Services (CMS) have labeled
30-day readmission rates as a measure of healthcare
quality and emphasize its reduction as a strategy to re-
duce healthcare costs while also maintaining quality
[7]. On October 1, 2012, CMS launched its Hospital
Readmission Reduction Program, an item under the
Patient Protection and Affordable Care Act [8]. This
program determines hospital reimbursements based on
five specific readmission measures: heart failure, acute
myocardial infarction, pneumonia, total hip/knee
arthroplasty, and COPD exacerbation [8] and hospitals
with “excessive” readmissions are penalized [8].
Currently, it is estimated that 25% of all hospital-
ized patients have DM [3, 9, 10], but data on 30-day
readmission rates for patients with DM is only just
emerging. Direct medical costs due to DM were $176
billion in 2012, of which 43% was generated via in-
patient care [11]. Ozieh and colleagues estimated that
the United States spent approximately $218.6 billion
per year in total direct health care expenditures for
patients with DM and $46 billion per year in total in-
cremental expenditures (adjusted) from 2002 to 2011,
significantly higher than in those without DM [12].
The major proportion of this expense was from hos-
pital admission and prescriptions [12]. Readmissions
were a significant contribution to these expenditures.
Compared to patients without DM, patients with DM
were more likely to be readmitted with other comor-
bid conditions such as heart failure, myocardial in-
farction, and cardiac surgery [13]. In recent studies,
the 30-day readmission rate for hospitalized patients
with DM is estimated to be 14.4–22.7% [14–18],
much higher than the rate for all hospitalized patients
(8.5–13.5%) [19, 20].
To best address this discrepancy in readmission, it is
important to determine the underlying causes of re-
admission in patients with DM. Some factors identified
include having health care insurance [18, 21–23], the
type of insurance (government vs. private or no insur-
ance) [18, 23], male gender [18, 22, 24, 25], length of
hospital stay [18, 21, 24, 26, 27], and degree of comor-
bidities [18, 24–26]. However, there is sparse evidence in
the literature of contributing clinical factors and specific
interventions to help decrease readmission rates, and
therefore, strategies to resolve these factors and reduce
30-day readmissions are not commonly developed or
employed.
Over the last decade, several institutions have created
specialized DM teams for treatment of patients with
DM, but few have reported on what percentage and
which groups of hospitalized patients with DM benefit
from these teams for outcomes specifically related to
readmission. To evaluate the readmission rates of pa-
tients with DM at UMHS, we collected two sets of data
- a three-month pilot data set followed by a one-year
dataset. Baseline readmission rates in patients with a
primary or secondary diagnosis of DM were evaluated
to determine if there were different causes for readmis-
sion between these groups. Additionally, we also evalu-
ated baseline characteristics of patients who were
readmitted and how many of them were cared for by
either of our DM services.
This project has two specific aims:
(1) Determine the incidence and causes of 30-day re-
admission rates for patients with a primary and second-
ary diagnosis of DM compared to those without DM
and (2) Evaluate the impact on readmission of two spe-
cialized inpatient DM services: the Hyperglycemic Inten-
sive Insulin Program (HIIP) and Endocrine Consults
(ENDO).
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Methods
DM was defined as any medical ICD-9 discharge diagno-
sis (principal or secondary) of 250.xx. Encounters con-
sidered as a 30-day unscheduled readmission were either
an “inpatient” admission, or an emergency department
(ED) visit, or observation unit stay. ED visits and obser-
vation encounters were combined and labeled as “other”
readmission encounter.
As described above, we evaluated two separate sets of
patient data. The first, a pilot retrospective chart review of
all patients admitted to any adult service within UMHS
was conducted for a three month period, between October
1, 2013 and December 31, 2013. For the pilot data we
compared readmission rates for patients with either a
principal or a secondary diagnosis of DM to those without
known DM. Both groups were examined for differences in
rates of inpatient and emergency department /observation
unit visits. Within this pilot data, we further performed
extensive manual chart review and an uncontrolled ana-
lysis of patients whose primary admission diagnosis was
DM related, and compared those readmitted with those
not readmitted, based on age, sex, race, length of stay
(LOS), discharge disposition, admitting service, discharge
service (both on index), type of DM, type of DM consult
(HIIP, ENDO, or no consult) Statistical analysis was per-
formed using SPSS version 19. Results are shown as mean
(SD) or percentages. T-tests were used to compare
continuous variables and chi-square was used to compare
categorical variables. A p-value of 0.05 was considered
significant.
The second group of patient data was collected from a
longer time frame and included inpatient adults (ages ≥
18) who were discharged from UMHS between October
1, 2013 and September 30, 2014 with any discharge diag-
nosis of DM (ICD-9-CM: 250.xx). This included the sub-
jects from the pilot group. Electronic medical records
were used to gather demographic and encounter-based
data. Case mix index was derived from Medicare weight
per Medicare Severity Diagnosis Related Groups (MS-
DRGs).
This study population was categorized based upon
the type of DM consult service received during the
index encounter: a) no HIIP or Endo, b) HIIP only, c)
Endo only or d) both HIIP and Endo. LOS was calcu-
lated as days between the date patients arrived at the
hospital, or ED arrival time if patients were admitted
via the ED and their discharge date. Case mix index is
based on most recent Medicare weight per MS-DRG.
Bivariate analysis was carried out between various
groups based on HIIP-Endo categorization. Wilcoxon
rank-sum tests were conducted when comparing con-
tinuous variables; and Fisher’s exact tests were per-
formed for categorical variables. Readmission within
30 days for both patient groups was calculated for
patients who were discharged alive from the index
encounter.
This study was exempt by the University of Michigan
Institutional Review Board.
University of Michigan (UMHS) Specialized DM
Teams.
The HIIP service is a multidisciplinary team led by a
team of endocrinology faculty from UMHS and also in-
cludes four midlevel providers (Physician Assistants,
Nurse Practitioners) as well as endocrine fellows. This
service sees post-surgical patients who are status-post
cardiac, vascular or thoracic surgery, and post-heart or
lung transplant. In addition, those who are not post-
surgical and have cystic fibrosis or heart failure with DM
and/or hyperglycemia are also seen. This team consists
of midlevel providers and endocrine faculty directly in-
volved in the management of their patients through
multiple daily patient interactions and education. Also
the providers have the ability to write DM related orders
for patients on this service. Post-discharge follow-up by
phone and in clinic is also managed by this group for a
few months until the patient is clinically stable and can
go back to their primary care or endocrine providers. In
contrast, ENDO is managed by the first-year endocrine
fellow and UMHS clinical faculty. The ENDO team gener-
ally sees patients who are not seen by the HIIP service
(e.g. general medicine, obstetrics, psychiatry, orthopedic
surgery) and leaves consult recommendations with the pa-
tient’s primary team. The ENDO team does not write or-
ders and has a narrower educational role. Post-discharge
support is coordinated with the primary service.
Results
Three-month pilot study – focus on principal diagnosis
of DM
There were a total of 7763 admissions between 10/1/
2013 and 12/31/2013 of which, 97.3% (7554) were dis-
charged alive and 25% had a diagnosis of DM. Patients
with any diagnosis of DM on index admission had
higher overall 30 day readmission rates (Inpatient plus
other) of 26.4% compared to patients without DM of
22.6% (p < 0.001). Inpatient readmission rates were sig-
nificantly higher amongst patients with either a primary
or a secondary diagnosis of DM (344/1940 or 18%) than
those without DM (775/5823 or 13.7%). Patients with a
primary, secondary, or no known diagnosis of DM had
readmission rates of 40.5, 25.8 and 22.5%, respectively.
Those with a primary diagnosis of DM had the highest
overall readmission rate, significantly greater for both
inpatient and ED/observation unit encounters (p < 0.001
and 0.02) respectively (Table 1).
We further evaluated the group of patients with a pri-
mary diagnosis of DM (n = 121) (Table 2, Appendix).
Their mean age was 50 years, and 67% had acute or
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chronic renal disease. 30% were admitted for a surgical
procedure, and the majority (95%) received insulin while
inpatient. Of those who had a recent hemoglobin A1c
test, the majority were uncontrolled as defined by a
HbA1c > 7.0% (74.4%). Only 28% of patients with a pri-
mary diagnosis of DM were seen by either the HIIP or
ENDO service for DM management. 26% (31/121) of pa-
tients with a primary diagnosis of DM were readmitted
and the major cause for readmission was DM-related
(Table 3).
The demographic distribution of the 121 encounters
with a primary diagnosis of DM is described in Table 4
by readmission status (readmitted vs. not-readmitted).
The two groups were similar for age, sex, race, type of
DM, and length of stay. On univariate analysis, there
were no statistically significant differences between the
readmitted and not readmitted groups for admitting or
discharging service, insurer, or discharge disposition.
Twelve-month study- focus on secondary diagnosis of DM
In our larger data set there were 37,702 adult inpatient
discharges between October 1, 2013 and September 30,
2014 and 21% (7872) of patients had known DM (Table 5).
Readmission rates for all encounters (inpatient, ED and
Observation care) were 24.5% in patients with DM and
17.7% in those without DM (p < 0.001). The 30-day read-
missions for DM for an inpatient and other (ED plus ob-
servation unit), were 17.5 and 9.3%, respectively. Patients
with DM were significantly more likely to be readmitted
compared to patients without DM for all three encounter
types (p < 0.001). During the index hospital stay, 12% of
patients with DM received a DM service consult; (9.6% by
HIIP and 3.2% by ENDO) (Table 5).
Amongst the readmitted patients, a similar proportion
of 12% (243/1846) had received a DM service consult
during index admission. There was a lower rate of ED
/observation readmission rate in patients followed by the
DM services, the bulk of contribution being from HIIP
(p = 0.0012). There was no difference in the inpatient re-
admission rates in patients with a DM consult vs. those
without (p = 0.8953). The 30-day all-cause inpatient un-
scheduled readmission rate was 17.4% for HIIP group,
compared to 14.8% for ENDO group (p = 0.3733).
Table 1 Pilot study data – readmission rates by DM diagnosis for patients with index admission between 10/1/2013 and 12/31/2013
Principal Dx of DM (n) Secondary Dx of DM (n) p-value Any DM No DM Dx (n) p-value
Index discharge
N = 7763
121 1819 1940 5823
Discharged alive
N = 7554
121 1757 1878 5676
30 day Readmissionsa n (%) n (%) n (%)
Inpatient readmission 31(25.6) 313(17.8) 0.02‡ 344(18) 775(13.7) <0.001‡†#
Other encounters 18(14.9) 141(8) 0.005‡ 159(8.4) 504(8.9) 0.02b
0.23c
Total 49(40.5) 454(25.8) 503(26.8) 1279(22.5)
Endocrine HIIP service 34(28) 275(15) 309(16) 97(1.7) <0.001
aAmong patients discharged alive; bComparison made to primary diagnosis of DM group; cComparison made to secondary diagnosis of DM; #any DM vs. no DM
Table 2 Baseline characteristics of patients admitted with a
primary diagnosis of DM
N = 121 Mean %
Age ( years) 49.7
Inpatient LOS (days) 4.7
Female 54 44.6
With renal disease (acute or chronic) 81 66.9
HbA1c performed within 2 months prior to
index encounter
43 35.5
HbA1c > 7.0% (among patients with HbA1c) 32 74.4
HbA1c > 10.0% 13 30.2
During index encounter
Undergoing surgical procedure 37 30.6
Receiving insulin 115 95.0
Endocrine (HIIP/Endo) consulta/office visit
During index encounter 34 28.1
Endocrine post-discharge appointment scheduled 31 25.6
Endocrine office visit billed 8 6.6
aEndocrine consult here refers to either a HIIP consult or Endocrine consult;
Note: n = 121 refers to the number of encounters, not the number of
individuals, some individuals had more than one readmission
Table 3 Principal diagnosis for inpatient readmission encounters





Renal disease = 19.4%
Other = 25.8%
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The demographic characteristics of adults with DM who
were discharged between October 1, 2013 and September
30, 2014, separated by the consult received, are provided
in Table 6. Of the 7605 DM patients discharged alive, the
average age was 62.7 years old, 56% were male and 48%
had acute or chronic renal insufficiency. The mean LOS
for all patients was 6.5 days. Only a small percentage
(13.7%) of patients received a DM-related consult.
The average LOS for all patients was 6.5 days and
average CMI was 2.10. When the DM groups were sepa-
rated by service received, the shortest LOS was among
patients who did not receive HIIP or ENDO services
(5.8 days) as was the lowest CMI at 1.84. . Patients who
received HIIP services only had an average LOS of
11.1 days, ENDO only 7.8 days. The longest average
LOS among those who received both HIIP and ENDO
services (19.3 days), and the average CMI of this group
was 5.54 which means that this complex patient group
which transferred through many different services.
Again the increased clinical severity of the patient
population serviced by HIIP and the combined group is
reflected in the higher CMI and LOS. Despite the com-
plexity of this group, they still had a lower rate of ED/
observation readmissions.
The median LOS and CMI of patients based on
whether and type of DM consult they received is shown
in Table 7. Patients who did not receive HIIP or ENDO
had significantly shorter median LOS (4 vs. 7 days respect-
ively, p < 0.0001) and CMI than those who received
HIIP or ENDO consult ENDO (1.35 vs. 2.28 respect-
ively, p < 0001), (Table 6).
We also evaluated the principal reasons for readmission
in this large cohort (Table 8). The most common causes
included infections (septicemia, postoperative infections,
urinary tract infections, pneumonia, Clostridium difficile,
and venous line infections), acute renal failure, complica-
tions of transplant, heart failure exacerbation, myocardial
infarctions, and DM-related complications.
Discussion
The prevalence of DM continues to increase in the United
States and presents a growing problem for health care [1].
It is a significant financial burden for patients, health care
providers and society. Nearly a quarter of hospitalized pa-
tients have DM, leading to increased mortality, morbidity,
and hospital complications [3]. Patient with DM have
higher early readmission rates compared to the general
population. Thirty-day readmission rates are a key quality
indicator. We therefore chose to evaluate the prevalence
of DM in our hospital population and the frequency and
reasons for readmissions. Understanding the factors asso-
ciated with early readmission in patients with DM will en-
able the development and implementation of strategies to
reduce readmission rates in this high risk population. This
study contributes to the limited body of literature on 30-
day readmission rates in patients with DM and determines
the incidence and causes of 30-day readmissions for pa-
tients with a primary or secondary diagnosis of DM and
evaluates the impact on readmission of specialized in-
patient DM services.
Twenty five percent of admitted patients had a pri-
mary or secondary diagnosis of diabetes in our pilot
study and twenty one percent in our larger study. These
rates are consistent with the literature [5]. Patients with
either a primary or secondary diagnosis of DM were
significantly more likely to be seen within 30 days of
discharge compared to patients without DM for all three
encounter types: inpatient admission, observation
Table 4 Demographic description at index encounter based on
readmission status (n = 121)
Readmitted (44) Not-readmitted (77) P-value
Age(y)Mean ± S.D 49.3 ± 15 50 ± 18 0.85
Sex (M/F) 24/20 43/34 0.89
Race (Black/non-black) 15/29 23/54 0.63
DM (T1/T2) 20/24 32/45 0.67
Length of stay 5.8 ± 6 4.1 ± 4 0.09
Table 5 Unscheduled readmissions by type of DM consult received
Unscheduled Readmission
Consult type Index discharge Inpatient encounter Other encounter Any encounter
N% p-value n% p-value n% p-value
All Inpatient adult discharges 36,820 4798 (13) - 2908(7.9) - 7009(19) -
Inpatient adult discharges without DM 29,215 (79.4) 3468(11.9) <0.001* 2204 (7.5) <0.001* 5163(17.7) <0.001*
Inpatient adult discharge with DM 7605 (20.6) 1330(17.5) - 704 (9.3) - 1846(24.3) -
No HIIP/Endo 6559 1142(17.4) – 632(9.6) – 1606(24.5) –
Either HIIP/Endo 1046 184(17.6) 0.8953 69(6.6) 0.0012 234(22.4) 0.1398
HIIP only 728 127(17.4) 1.000 41(5.6) 0.0003 159 (21.8) 0.1211
Endo only 243 36(14.8) 0.342 19(7.8) 0.436 46(18.9) 0.0477
All p-values represent comparison of the readmission rate for patients who received no HIIP or endocrine consult to other consult categories; *These p-values
compare the overall readmission rate for each encounter type (shaded row) to the readmission rate for inpatient adult discharge without DM
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admission and ED visit. Patients with a primary, second-
ary, or no known diagnosis of DM had readmission rates
of 40.5, 25.8 and 22.5%, respectively. This very high re-
admission rate in patients with an index admission for
diabetes highlights the importance of improving our un-
derstanding of the reasons for readmission in patients
admitted with a principal diagnosis of diabetes.
In our pilot study we found that in patients with a prin-
cipal diagnosis of DM, most required insulin, roughly
two-thirds had renal disease and almost a third had very
poorly controlled diabetes with an A1C > 10%. Despite
this only 28% had a DM related consult at index encoun-
ter and only 25% had a follow up appointment scheduled
for DM- related service. Only 6.6% actually followed up.
Since diabetes was the principal reason for readmission in
35.4% of readmission for patients with a principal diagno-
sis of diabetes on index admission, the involvement of
DM related services in the hospital and on discharge may
have reduced the readmission outcome.
In the larger study where we evaluated patients with
secondary diagnosis of DM, infections were the over-
whelming cause of readmission. Multiple studies have
shown that diabetes is a significant risk factor for infection
[28]. Furthermore, good glycemic control perioperatively
has been shown to reduce surgical site infections [29].
However, we were unable to determine the relative
contribution of various risk factors such as glycemic con-
trol, immunosuppression and infections in this analysis.
Since we did not evaluate hospital glucose control, the ef-
fect of glycemic management by DM services on readmis-
sion is not possible to evaluate. Twelve percent of patients
with DM as a secondary diagnosis received either a HIIP
or ENDO consult during the index admission. There were
no significant differences between type of inpatient dia-
betes consult on inpatient admissions. However, patients
who received either a HIIP or ENDO consult, or those
who received only a HIIP consult, were significantly less
likely to have an emergency department visit or observa-
tion unit stay. Patients with a HIIP consult had higher
complexity with significantly higher case mix index than
those with either an ENDO or no consult (4.12 for HIIP
vs. 1.99 for ENDO and 1.84 for no consult). They also had
longer LOS reflecting their case complexity and comor-
bidities (11.0 for HIIP vs. 7.6 or ENDO and 5.6 for no
consult). In assessing these data it is important to consider
that the patients populations based on type of DM consult
(HIIP vs ENDO vs neither) varied immensely and we
could not control all these factors for outcomes. In
addition there were several other limitations in our study.
It is a retrospective review and data are derived from the
data warehouse and chart review. Patients without a bill-
ing diagnosis of DM who had known DM would not be
Table 6 Demographic information of patients with DM
Total (n)
N(%)
No HIIP, No ENDO HIIP only ENDO only HIIP or ENDO Both HIIP and ENDO
Discharged 7872 6804 745 245 1068 78
Discharged alive 7605 (96.6%) 6559 (96.4%) 728 (97.7%) 243 (99.2%) 1046 (97.9%) 75 (96.2%)
Among discharged alive
Avg age 62.7 63.2 61.6 53.1 59.3 57.1
Race -black 1206 (15) 1076 (16.4) 87 (12) 33 (13.6%) 130 (12.4%) 10
13.3%
Gender – M 4231 (55.6) 3582 (54.6) 470(65.6) 133 (54.7%) 649 (62%) 46
61.3%
Renal Ds. 3719 (48.) 3153 (48.1) 400 (54.9) 118 (48.6%) 566(54.1) 48 (64.0%
Mean LOS-days 6.5 5.8 11.1 7.8 10.9 19.3
Case mix index 2.10 1.84 4.12 1.99 3.73 5.54
Median Case mix index 1.47 1.35 2.82 1.54 2.28 2.39
Race – black 1.30 1.22 1.92 1.12 1.54 0.83
Race – non-black 1.51 1.38 3.00 1.56 2.55 3.15
Table 7 Comparison of inpatient length of stay and case mix index to ‘No HIIP, No ENDO’
Total No HIIP, No ENDO HIIP only P-value ENDO only P-value HIIP or ENDO P-value
Median
Inpatient LOS
4 4 7 <0.0001 5 <0.0001 7 <0.0001
Median Case Mix Index 1.47 1.35 2.82 <0.0001 1.54 <0.0001 2.28 <0.0001
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included and therefore we may not have captured all pa-
tients with DM. While there were some direct compari-
sons between HIIP only and endocrine only groups, it is
important to note that these two consult groups service
very different patient populations. Finally, data that was
collected represents only a single, academic institution
and may not be representative of patients with DM at
other institutions. This is one of the first studies evaluat-
ing DM readmissions separated by a primary and second-
ary diagnosis of DM and finding that they have separate
reasons for readmissions.
Future prospective controlled studies evaluating read-
missions in DM patients and controlling for glycemic
management, other comorbidities and managed with
and without a DM service may help determine other
modifiable risk factors associated with early readmission.
Identifying and understanding several of these factors
will help devise DM services to tailor care to hospital
glucose control and beyond into education and close
post-discharge follow-up with the intention of reducing
early readmission.
Conclusion
Patients with a primary and secondary diagnosis of DM
have higher readmission rates than patients without
known DM. Reasons for readmission varied, those with
a principal admitting diagnosis having more readmis-
sions with diabetes related issues while those with a sec-
ondary admitting diagnosis of diabetes having more
infection-related readmissions. DM services were uti-
lized in very small proportion of patients with DM and
may have contributed to lower ED revisits by providing
more robust diabetes management, discharge planning
and instruction. Their impact on readmission in pro-
spective studies needs to be evaluated.
Appendix
Appendix xx. Diagnosis codes for renal diseases (from
Leapfrog – VB 2011)







CMI: Case mix index; CMS: Centers for Medicare and Medicaid Services;
DM: Diabetes mellitus; DVT: Deep vein thrombosis; DX: Diagnosis;
ED: Emergency department; ENDO: Endocrine Consult Service;
GI: Gastrointestinal; HIIP: Hyperglycemic Intensive Insulin Program;
LOS: Length of stay; MS-DRGs: Medicare Severity Diagnosis Related Groups;
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